Opendata, web and dolomites

BGV1 SIGNED

New vaccine for a paradigm shift in Brucellosis, one of the world’s most widespread zoonotic diseases affecting humans

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BGV1 project word cloud

Explore the words cloud of the BGV1 project. It provides you a very rough idea of what is the project "BGV1" about.

zoonotic    overcomes    rising    diagnostic    amidst    serious    combined    time    bioterrorism    cumulative    health    brucella    unnecessary    treatable    vaccine    drawbacks    animal    shift    vaccination    paradigm    virulent    avirulent    species    radical    benefits    brucellosis    lactating    science    greenvac    endemic    designed    tests    successful    infection    human    replace    anyone    ruminants    relatively    safety    prevalent    profile    antibiotics    candidate    latin    first    america    world    losses    africa    regions    evading    global    classic    transmissibility    economic    mainly    livestock    disease    anywhere    2028    serodiagnostic    livelihoods    bgv1    enhanced    exhibiting    safe    resistance    diagnostics    lower    melitensis    integration    lives    caused    veterinary    generate    incidence    threats    mass    antibiotic    globalisation    small    pregnant    mediterranean    minimal    vaccines    rate    virulence    suffer    humans    1950s    protective    eradication    efficacy    interference    81bn    impacts    asia    animals    residual    poor    outbreaks    standard    severely    environmental    eliminate    keepers    limited    medicine   

Project "BGV1" data sheet

The following table provides information about the project.

Coordinator
BRUCELLA GREEN VAC SL 

Organization address
address: PLAZA LAMITURRI, 10, 1 A
city: MUTILVA
postcode: 31192
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 2˙005˙250 €
 EC max contribution 1˙403˙675 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-SMEInst-2018-2020-3
 Funding Scheme SME-2b
 Starting year 2020
 Duration (year-month-day) from 2020-03-01   to  2022-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BRUCELLA GREEN VAC SL ES (MUTILVA) coordinator 1˙403˙675.00

Map

 Project objective

Brucellosis is the world’s most widespread zoonotic disease. It is a global problem but most severely affects poor livestock keepers in the developing world because of its impacts on human and animal health and livelihoods. Brucellosis is endemic in most of Asia, Africa and Latin America and is prevalent in the EU Mediterranean regions. Currently vaccines for Brucellosis, around since the 1950s, suffer from serious safety drawbacks mainly due to residual virulence for animals and humans. Combined with rising antibiotic resistance, their use is relatively limited.

GreenVac is developing BGV1, the first vaccine in over 60 years against Brucella melitensis in small ruminants that overcomes the main drawbacks of existing vaccines. BGV1 has been designed to a) be avirulent for animals, b) eliminate interference with diagnostic tests after vaccination, c) have low potential transmissibility to humans and, d) be treatable with standard antibiotics. BGV1 is a strong candidate to replace the classic virulent vaccine, exhibiting a safe profile with an enhanced protective efficacy, no residual virulence and minimal serodiagnostic interference.

A successful BGV1 EU-project will allow, for the first time, mass vaccination of any animal at any time (including pregnant and lactating animals), which is a radical paradigm shift in Brucellosis control and eradication. The reduction of B. melitensis outbreaks and infection rate in animals will generate €3.81bn in cumulative economic benefits for users by 2028 by evading unnecessary diagnostics costs and losses caused by the infection. It will lead to a lower disease incidence in humans amidst ever rising globalisation and bioterrorism threats to anyone, anywhere. BGV1 will contribute to the objectives of the One Health Initiative: One World, One Health, One Medicine to improve the lives of all species through the integration of human medicine, veterinary medicine and environmental science.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BGV1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BGV1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ELDICO ED (2019)

ELDICO ED, Shaping the Future of Crystallography - The First Pure Electron Diffraction Equipment for Nano-Crystallography

Read More  

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

DetectInMen (2019)

Infection detection in human semen

Read More